The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.本發明提供經單離之單株抗體，尤其係人類單株抗體，其以高親和性專一性地與PD－1結合。亦提供編碼本發明抗體之核酸分子、表現載體、宿主細胞及表現本發明抗體之方法。亦提供包括本發明抗體之免疫接合物、雙專一性分子及醫藥組成物。本發明亦提供偵測PD－1之方法，以及利用抗－PD－1抗體治療各種疾病(包含癌症及感染性疾病)之方法。本發明進一步提供利用組合免疫療法(例如抗－CTLA－4與抗－PD－1抗體之組合)治療過度增生性疾病(例如癌症)之方法。本發明亦提供改變關於個別以此等抗體治療之不良後果之方法。
